The National Advertising Division (NAD) of BBB National Programs announced it will refer Maze Therapeutics, Inc. to appropriate regulatory authorities for review and possible enforcement action. This referral follows Maze's failure to submit a substantive response to an NAD inquiry.
The inquiry stemmed from a challenge brought by Vertex Pharmaceuticals Incorporated regarding express and implied claims made by Maze in investor presentations, press releases, and public filings. Vertex questioned Maze’s claims concerning the efficacy of its APOL1-Mediated Kidney Disease (AMKD) treatment, MZE829, compared to Vertex’s drug candidate, inaxaplin.
Maze declined to participate in the NAD process, stating it does not currently sell any product or advertise MZE829. This referral to government agencies could impact the competitive landscape for AMKD treatments, where both Vertex and Maze are developing clinical-stage therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.